» Articles » PMID: 38419283

Case Series: Stenotrophomonas Maltophilia in Pediatric Oncology Patients

Overview
Specialty Oncology
Date 2024 Feb 29
PMID 38419283
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Stenotrophomonas maltophilia is a bacterial pathogen that can be fatal in hospitalized and immunocompromised patients with mortality as high as 69%. Pediatric cancer patients often have risk factors that are common for this infection, making them particularly susceptible. Managing S. maltophilia is especially challenging as it has inherent resistance to several antibiotics. Furthermore, soft tissue infections in neutropenic patients may deviate from the typical clinical presentation of S. maltophilia.

Case Details: This case series describes an in-depth examination of three cases involving immunocompromised pediatric patients with S. maltophilia infections. Each case exhibited a distinct clinical presentation, encompassing infection of the blood, lung, and skin, which highlights the variability in which S. maltophilia manifests in immunocompromised pediatric patients. These patients were treated at MD Anderson Cancer Center (MDACC) from 2020 to 2023, unfortunately resulting in fatality.

Conclusions: The study aims to provide valuable insights and guidance for the management of patients with S. maltophilia infections. Emphasizing a heightened clinical suspicion will potentially lead to early initiation of directed therapy against S. maltophilia. Timely intervention may play a pivotal role in improving patient outcomes and reduce further burden to the healthcare system.

Citing Articles

Case series: Stenotrophomonas maltophilia in pediatric oncology patients.

Sarkar S, Stitzlein L, Rav E, Garcia M, Razvi S, Chang M Cancer Rep (Hoboken). 2024; 7(3):e1982.

PMID: 38419283 PMC: 10913069. DOI: 10.1002/cnr2.1982.


Hemorrhagic Pneumonia Caused by in Patients with Hematologic Malignancies-A Systematic Review and Meta-Analysis.

Huang C, Kuo S, Lin L Medicina (Kaunas). 2024; 60(1).

PMID: 38256422 PMC: 10819368. DOI: 10.3390/medicina60010162.

References
1.
Ibrahim D, Jabbour J, Kanj S . Current choices of antibiotic treatment for Pseudomonas aeruginosa infections. Curr Opin Infect Dis. 2020; 33(6):464-473. DOI: 10.1097/QCO.0000000000000677. View

2.
Lin S, Zhang C, Ye S . Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies. Int J Clin Pharm. 2018; 40(5):1030-1036. DOI: 10.1007/s11096-018-0690-0. View

3.
Jeon Y, Jeong W, Kim M, Jung I, Ahn M, Ann H . Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Medicine (Baltimore). 2016; 95(31):e4375. PMC: 4979800. DOI: 10.1097/MD.0000000000004375. View

4.
Tada K, Kurosawa S, Hiramoto N, Okinaka K, Ueno N, Asakura Y . Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage. Bone Marrow Transplant. 2012; 48(1):74-9. DOI: 10.1038/bmt.2012.87. View

5.
Averbuch D, Avaky C, Harit M, Stepensky P, Fried I, Ben-Ami T . Non-fermentative Gram-negative rods bacteremia in children with cancer: a 14-year single-center experience. Infection. 2017; 45(3):327-334. DOI: 10.1007/s15010-017-0988-1. View